MBX Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of 21.47%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Johnson & Johnson's return on equity of 33.27%.

MBX Biosciences, Inc. has a consensus price target of $59.25, signalling upside risk potential of 91.75%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that MBX Biosciences, Inc. has higher upside potential than Johnson & Johnson, analysts believe MBX Biosciences, Inc. is more attractive than Johnson & Johnson.

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. MBX Biosciences, Inc.'s net income of -$21.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of -39.75%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

MBX Biosciences, Inc. has a consensus price target of $59.25, signalling upside risk potential of 91.75%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 0.76%. Given that MBX Biosciences, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe MBX Biosciences, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. MBX Biosciences, Inc.'s net income of -$21.6M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 17.93x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sonnet BioTherapeutics Holdings, Inc. has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of -316.07%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Sonnet BioTherapeutics Holdings, Inc.'s return on equity of -669.7%.

MBX Biosciences, Inc. has a consensus price target of $59.25, signalling upside risk potential of 91.75%. On the other hand Sonnet BioTherapeutics Holdings, Inc. has an analysts' consensus of $20.00 which suggests that it could grow by 1487.3%. Given that Sonnet BioTherapeutics Holdings, Inc. has higher upside potential than MBX Biosciences, Inc., analysts believe Sonnet BioTherapeutics Holdings, Inc. is more attractive than MBX Biosciences, Inc..

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sonnet BioTherapeutics Holdings, Inc. has a beta of 1.478, suggesting its more volatile than the S&P 500 by 47.817%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sonnet BioTherapeutics Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Sonnet BioTherapeutics Holdings, Inc. pays out -- of its earnings as a dividend.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Sonnet BioTherapeutics Holdings, Inc. quarterly revenues of --. MBX Biosciences, Inc.'s net income of -$21.6M is lower than Sonnet BioTherapeutics Holdings, Inc.'s net income of -$5.6M. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Sonnet BioTherapeutics Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 5.35x for Sonnet BioTherapeutics Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ARS Pharmaceuticals, Inc. has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of -157.38%. MBX Biosciences, Inc.'s return on equity of -29.36% beat ARS Pharmaceuticals, Inc.'s return on equity of -38.98%.

MBX Biosciences, Inc. has a consensus price target of $59.25, signalling upside risk potential of 91.75%. On the other hand ARS Pharmaceuticals, Inc. has an analysts' consensus of $28.67 which suggests that it could grow by 151.9%. Given that ARS Pharmaceuticals, Inc. has higher upside potential than MBX Biosciences, Inc., analysts believe ARS Pharmaceuticals, Inc. is more attractive than MBX Biosciences, Inc..

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ARS Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ARS Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. ARS Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than ARS Pharmaceuticals, Inc. quarterly revenues of $32.5M. MBX Biosciences, Inc.'s net income of -$21.6M is higher than ARS Pharmaceuticals, Inc.'s net income of -$51.2M. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while ARS Pharmaceuticals, Inc.'s PE ratio is 174.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 7.83x for ARS Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.